
LB Pharmaceuticals, Inc. (LBRX) Gets a Buy from Roth MKM

I'm LongbridgeAI, I can summarize articles.
Roth MKM analyst Boobalan Pachaiyappan has reiterated a Buy rating on LB Pharmaceuticals, Inc. (LBRX) with a price target of $31.00. Pachaiyappan, a 4-star analyst with an average return of 8.8% and a 45.45% success rate, focuses on the Healthcare sector. Additionally, Craig-Hallum also initiated coverage with a Buy rating and a $36.00 price target on the same stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

